

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

|                               |   |
|-------------------------------|---|
| <b>Drug</b>                   | <b>Ombitasvir-paritaprevir-ritonavir and dasabuvir</b>  |
| Brand Name                    | Holkira™Pak   |
| Dosage Form(s)                | 12.5 mg/75 mg/50 mg (ombitasvir-paritaprevir-ritonavir) and 250 mg (dasabuvir) oral tablets   |
| Manufacturer                  | AbbVie Corporation  |
| <b>Submission Review</b>      | <b>New Submission</b>   |
| Use Reviewed                  | Chronic Hepatitis C (CHC) genotype 1 infection  |
| Common Drug Review (CDR)      | CDR recommended to: <b>List with criteria and conditions.</b><br>Visit the CDR website for more details: <a href="http://www.cadth.ca/node/88649">www.cadth.ca/node/88649</a> .   |
| Drug Benefit Council (DBC)    | DBC now screens drug submissions under review by CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined not to be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and internal review only. The DBC screened Holkira™Pak on March 2, 2015. The DBC advised that because ombitasvir-paritaprevir-ritonavir and dasabuvir is similar to some of the other drugs for the treatment of CHC genotype 1, the Ministry may accept CDEC's ombitasvir-paritaprevir-ritonavir and dasabuvir recommendation.  |
| <b>Drug Coverage Decision</b> | <b>Limited Coverage Benefit</b><br><b>Access the ombitasvir-paritaprevir-ritonavir and dasabuvir criteria from <a href="http://www.gov.bc.ca/pharmacarespecialauthority">www.gov.bc.ca/pharmacarespecialauthority</a>.</b>  |
| Date                          | July 28, 2015   |
| Reason(s)                     | <b>Drug coverage decision is consistent with CDEC recommendation.</b> <ul style="list-style-type: none"> <li>• Ombitasvir-paritaprevir-ritonavir and dasabuvir with or without ribavirin (RBV) reported high cure rates (based upon sustained viral response), is generally well-tolerated (compared to interferon-containing regimens) and offers a shorter duration of therapy for most patients.</li> <li>• Based on the CDR pharmacoeconomic report, ombitasvir-paritaprevir-ritonavir and dasabuvir is similar in cost-effective compared to ledipasvir-sofosbuvir.</li> <li>• Ombitasvir-paritaprevir-ritonavir and dasabuvir, with or without RBV, offers an alternative all-oral, interferon-free therapeutic option for CHC genotype 1 infection.</li> </ul> |
| Other Information             | None  |

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) (DBC) gives advice to the Ministry. The DBC looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. [Drug Review Process](#) and [PharmaCare](#) program for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.